2. Academic Validation
  3. CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

  • NPJ Breast Cancer. 2025 Dec 3;11(1):135. doi: 10.1038/s41523-025-00851-7.
Nealia C House # 1,  Maxine M Chen # 2,  Sima Khazaei 3,  Victoria Brown 2,  Philip Ramsden 2,  David H Peng 3,  Sydney Moore 2,  Liang Yuan 2,  Rentian Wu 2,  Fangyang Wang 3,  Linjie Luo 4,  Ningping Feng 3,  Christopher A Bristow 3,  Timothy A Yap 5,  Khandan Keyomarsi 4,  Joseph R Marszalek 3,  Scott Ribich 2,  Mikael L Rinne 2,  Lakshmi B Muthuswamy 2,  Kerrie L Faia 2
Affiliations

Affiliations

  • 1 Blueprint Medicines Corporation, Cambridge, MA, USA. NHouse@blueprintmedicines.com.
  • 2 Blueprint Medicines Corporation, Cambridge, MA, USA.
  • 3 TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 4 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 5 Department of Investigational Cancer Therapeutics, Therapeutic Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • # Contributed equally.
PMID: 41339342 DOI: 10.1038/s41523-025-00851-7
Abstract

Aberrant cyclin-dependent kinase 2 (CDK2) activity is implicated as a resistance mechanism to CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast Cancer. Using preclinical patient-derived xenograft models, the CDK2i + CDK4/6i combination was active broadly across CDK4/6i-resistant and -naïve HR+ and triple-negative breast Cancer models. A novel, weighted mRNA expression signature involving CCND1, CCNE1, RB1, and CDKN2A (p16) predicted response to combined inhibition of CDK2 and CDK4/6. Addition of endocrine therapy significantly enhanced antitumor activity in HR+ models, providing preclinical proof-of-concept for the broad antitumor activity of the triple combination. Early clinical data demonstrated activity of BLU-222, a potent and selective CDK2 Inhibitor, both as monotherapy (CCNE1 amplified) and in combination with ribociclib and fulvestrant in patients with HR+/HER2- breast Cancer. These findings provide evidence that CDK2i combined with CDK4/6i can address multiple known mechanisms of resistance to CDK4/6i, enhancing antitumor responses in preclinical breast Cancer models.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z